m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer

References

• Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67(6):2254–2270.
   PubMed Web of Science ®Google Scholar
• Li J, Han Y, Zhang H, et al. Li B: the m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem Biophys Res Commun. 2019;512(3):479–485.
   PubMed Web of Science ®Google Scholar
• Hua W, Zhao Y, Jin X, et al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 2018;151(2):356–365.
   PubMed Web of Science ®Google Scholar
• Chen M, Nie ZY, Wen XH, et al. m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer. Biosci Rep. 2019 ;39(12):BSR20192892
   Google Scholar
• Ma S, Chen C, Ji X, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol. 2019;12(1):121.
   PubMed Web of Science ®Google Scholar
• Ma Z, Li Q, Liu P, et al. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol Int. 2020;44(12):2524–2531.
   PubMed Web of Science ®Google Scholar
• Li J, Wu L, Pei M, et al. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J Ovarian Res. 2020;13(1):111.
   PubMed Web of Science ®Google Scholar
• Fukumoto T, Zhu H, Nacarelli T, et al. N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance. Cancer Res. 2019;79(11):2812–2820.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1a):A68–77.
   PubMedGoogle Scholar
• Lonsdale J, Thomas J, Salvatore M, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–585
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678.
   PubMed Web of Science ®Google Scholar
• Wagner GP, Kin K, Lynch VJ. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci. 2012;131(4):281–285.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–1573.
   PubMed Web of Science ®Google Scholar
• Keenan AB, Torre D, Lachmann A, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47(W1(W1):W212–w224.
   Web of Science ®Google Scholar
• von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–261.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Kuehn H, Gould J, et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23(23):3251–3253.
   PubMed Web of Science ®Google Scholar
• Zuo S, Wei M, Zhang H, et al. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer. J Transl Med. 2019;17(1):152.
   PubMedGoogle Scholar
• Zhang M, Zhu K, Pu H, et al. An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma. Front Oncol. 2019;9:1314.
   PubMed Web of Science ®Google Scholar
• Loeb M, Bentley DW, Bradley S, et al. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. Infect Control Hosp Epidemiol. 2001 22;(2)120–124.
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5(9):735–741.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Sato Y, Kawashima M, et al. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1(D1):D457–462.
   Web of Science ®Google Scholar
• Liu Y, Wu L, Ao H, et al. Prognostic implications of autophagy-associated gene signatures in non-small cell lung cancer. Aging (Albany NY). 2019;11(23):11440–11462.
   PubMedGoogle Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
   Web of Science ®Google Scholar
• Liu Y, Yang Y, Luo Y, et al. Prognostic potential of PRPF3 in hepatocellular carcinoma. Aging (Albany NY). 2020;12(1):912–930.
   PubMedGoogle Scholar
• Li T, Fan J, Wang B, et al. TIMER: a Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77(21):e108–e110. e108-e110. .
   PubMed Web of Science ®Google Scholar
• Huang C, Liu Z, Xiao L, et al. Clinical Significance of Serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination. Front Oncol. 2019;9:1159.
   PubMed Web of Science ®Google Scholar
• Wu M, Li X, Zhang T, et al. Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer. Front Oncol. 2019;9:996.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–2123.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–574.
   PubMed Web of Science ®Google Scholar
• Burkett K, Pickler R, Bowers K, et al. Disparities Affect Developmental Risk for Head Start Preschoolers. J Pediatr Nurs. 2020;54::86–92.
   PubMed Web of Science ®Google Scholar
• Xu WH, Shi SN, Xu Y, et al. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma. J Transl Med. 2019;17(1):363.
   PubMed Web of Science ®Google Scholar
• Turner RB, Kojiro K, Shephard EA, et al. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients. Pharmacotherapy. 2018;38(12):1174–1183.
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V, et al. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: a Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2019;111(8):772–781.
   PubMedGoogle Scholar
• Liu J, Li S, Liang J, et al. ITLNI identified by comprehensive bioinformatic analysis as a hub candidate biological target in human epithelial ovarian cancer. Cancer Manag Res. 2019;11::2379–2392.
   Web of Science ®Google Scholar
• Liu WL, Zhao JZ, Wang ZZ, et al. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2017;52(6):403–410.
   PubMedGoogle Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.
   PubMed Web of Science ®Google Scholar
• Scaletta G, Plotti F, Luvero D, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther. 2017;17(9):827–839.
   PubMed Web of Science ®Google Scholar
• Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY et al. Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Mol Cell. 2016;61(4):507–519.
   PubMed Web of Science ®Google Scholar
• Fustin JM,M,, Yamaguchi Y, Hida H, et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell. 2013;155(4):793–806.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao BS, Roundtree IA, et al. N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015;161(6):1388–1399.
   PubMed Web of Science ®Google Scholar
• García-Cárdenas JM, Guerrero S, López-Cortés A, et al. Post-transcriptional Regulation of Colorectal Cancer: a Focus on RNA-Binding Proteins. Front Mol Biosci. 2019;6:65.
   PubMed Web of Science ®Google Scholar
• Wurth L, Papasaikas P, Olmeda D, et al. UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis. Cancer Cell. 2016;30(5):694–707.
   PubMed Web of Science ®Google Scholar
• Kakumani PK, Guitart T, Houle F, et al. CSDE1 attenuates microRNA-mediated silencing of PMEPA1 in melanoma. Oncogene. 2021;40(18):3231–3244.
   PubMed Web of Science ®Google Scholar
• Wurth L, Gebauer F. RNA-binding proteins, multifaceted translational regulators in cancer. Biochim Biophys Acta. 2015;1849(7):881–886.
   PubMed Web of Science ®Google Scholar
• Bisogno LS, Keene JD. RNA regulons in cancer and inflammation. Curr Opin Genet Dev. 2018;48::97–103.
   PubMed Web of Science ®Google Scholar
• Culjkovic-Kraljacic B, Borden KLB. The Impact of Post-transcriptional Control: better Living Through RNA Regulons. Front Genet. 2018;9:512.
   PubMed Web of Science ®Google Scholar
• Bay JO, Choufi B, Pomel C, et al. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant. 2000;25(6):681–682.
   PubMed Web of Science ®Google Scholar
• Hanel M, Bornhauser M, Muller J, et al. Evidence for a graft-versus-tumor effect in refractory ovarian cancer. J Cancer Res Clin Oncol. 2003;129(1):12–16.
   PubMed Web of Science ®Google Scholar
• Pasto A, Bellio C, Pilotto G, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014;5(12):4305–4319.
   PubMedGoogle Scholar
• Nayak AP, Kapur A, Barroilhet L, et al. Oxidative Phosphorylation: a Target for Novel Therapeutic Strategies Against Ovarian Cancer. Cancers (Basel). 2018;10(9.
   Web of Science ®Google Scholar
• Cai X, Wang X, Cao C, et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2018;415:11–19.
   PubMed Web of Science ®Google Scholar
• Vu LP, Pickering BF, Cheng Y, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369–1376.
   PubMed Web of Science ®Google Scholar
• Li X, Tang J, Huang W, et al. The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma. Oncotarget. 2017;8(56):96103–96116.
   PubMedGoogle Scholar
• Taketo K, Konno M, Asai A, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52(2):621–629.
   PubMed Web of Science ®Google Scholar
• Sun HL, Zhu AC, Gao Y, et al. Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m(6)A Methylation. Mol Cell. 2020;80(4):633–647.e637.
   PubMed Web of Science ®Google Scholar
• Scholler E, Weichmann F, Treiber T, et al. Interactions, localization, and phosphorylation of the m(6)A generating METTL3-METTL14-WTAP complex. RNA. 2018;24(4):499–512.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen C, Ding Q, et al. METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69(7):1193–1205.
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo X, Li L, et al. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020;11(10):911.
   PubMed Web of Science ®Google Scholar
• Yu HL, Ma XD, Tong JF, et al. WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells. Onco Targets Ther. 2019;12::6191–6201.
   Web of Science ®Google Scholar
• Chen L, Wang X. Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis. Oncol Lett. 2018;16(6):6966–6970.
   PubMed Web of Science ®Google Scholar
• Xi Z, Xue Y, Zheng J, et al. WTAP Expression Predicts Poor Prognosis in Malignant Glioma Patients. J Mol Neurosci. 2016;60(2):131–136.
   PubMed Web of Science ®Google Scholar
• Wang J, Xu J, Li K, et al. Identification of WTAP-related genes by weighted gene co-expression network analysis in ovarian cancer. J Ovarian Res. 2020;13(1):119.
   PubMed Web of Science ®Google Scholar
• Ma JZ, Yang F, Zhou CC, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65(2):529–543.
   PubMed Web of Science ®Google Scholar
• Wang M, Liu J, Zhao Y, et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N(6) adenosine methylation promoting the growth and metastasis of pancreatic cancer. Mol Cancer. 2020;19(1):130.
   PubMed Web of Science ®Google Scholar
• Sun T, Wu Z, Wang X, et al. LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020;39(31):5358–5372.
   PubMed Web of Science ®Google Scholar
• Chen X, Xu M, Xu X, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer. 2020;19(1):106.
   PubMed Web of Science ®Google Scholar
• Qian JY, Gao J, Sun X, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019;38(33):6123–6141.
   PubMed Web of Science ®Google Scholar
• Miao R, Dai CC, Mei L, et al. KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer. J Cell Physiol. 2020;235(10):7420–7432.
   PubMed Web of Science ®Google Scholar
• Cheng X, Li M, Rao X, et al. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA. Onco Targets Ther. 2019;12::3421–3428.
   Web of Science ®Google Scholar
• Zhu D, Zhou J, Zhao J, et al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. J Cell Physiol. 2019;234(6):8899–8907.
   PubMed Web of Science ®Google Scholar
• Gong PJ, Shao YC, Yang Y, et al. Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer. Front Oncol. 2020;10:578963.
   PubMed Web of Science ®Google Scholar
• Deng X, Su R, Stanford S, et al. Critical Enzymatic Functions of FTO in Obesity and Cancer. Front Endocrinol (Lausanne). 2018;9:396.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang Y, Sun BF, et al. FTO and obesity: mechanisms of association. Curr Diab Rep. 2014;14(5):486.
   PubMed Web of Science ®Google Scholar
• Akbari ME, Gholamalizadeh M, Doaei S, et al. FTO Gene Affects Obesity and Breast Cancer Through Similar Mechanisms: a New Insight into the Molecular Therapeutic Targets. Nutr Cancer. 2018;70(1):30–36.
   PubMed Web of Science ®Google Scholar
• Xu D, Shao W, Jiang Y, et al. FTO expression is associated with the occurrence of gastric cancer and prognosis. Oncol Rep. 2017;38(4):2285–2292.
   PubMed Web of Science ®Google Scholar
• Cho SH, Ha M, Cho YH, et al. ALKBH5 gene is a novel biomarker that predicts the prognosis of pancreatic cancer: a retrospective multicohort study. Ann Hepatobiliary Pancreat Surg. 2018;22(4):305–309.
   PubMedGoogle Scholar
• Zhang J, Guo S, Piao HY, et al. ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1. J Physiol Biochem. 2019;75(3):379–389.
   PubMed Web of Science ®Google Scholar
• Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6) A-demethylationof NANOG mRNA. Proceedings of the National Academy of Sciences of the United States of America 2016, 113( 14):E2047–2056.
   Google Scholar
• Zhu H, Gan X, Jiang X, et al. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019;38(1):163.
   PubMedGoogle Scholar
• Nishizawa Y, Konno M, Asai A, et al. Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer. Oncotarget. 2018;9(7):7476–7486.
   PubMedGoogle Scholar
• Chen J, Sun Y, Xu X, et al. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Cell Cycle (Georgetown, Tex). 2017;16(23):2259–2271.
   PubMed Web of Science ®Google Scholar
• Zhao X, Chen Y, Mao Q, et al. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomarkers. 2018;21(4):859–868.
   PubMed Web of Science ®Google Scholar
• Li J, Meng S, Xu M, et al. Downregulation of N(6)-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N(6)-methyladenosine levels. Oncotarget. 2018;9(3):3752–3764.
   PubMedGoogle Scholar
• Sheng H, Li Z, Su S, et al. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis. 2020 ;41(5):541–550.
   PubMed Web of Science ®Google Scholar
• Zhang J, Pi J, Liu Y, et al. [Knockdown of YTH N(6)-methyladenosine RNA binding protein 2 (YTHDF2) inhibits proliferation and promotes apoptosis in MGC-803 gastric cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33(12):1628–1634.
   PubMedGoogle Scholar
• Huang H, Han Y, Zhang C, et al. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. Tumour Biol. 2016;37(3):3527–3534.
   PubMedGoogle Scholar
• Kleemann M, Schneider H, Unger K, et al. MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells. Sci Rep. 2018;8(1):9020.
   PubMedGoogle Scholar
• Toss A, Tomasello C, Razzaboni E, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:341723.
   PubMed Web of Science ®Google Scholar
• Gleicher N, McAlpine JN, Gilks CB, et al. Absence of BRCA/FMR1 correlations in women with ovarian cancers. PLoS One. 2014;9(7):e102370.
   PubMed Web of Science ®Google Scholar
• Drakes ML, Stiff PJ. Understanding dendritic cell immunotherapy in ovarian cancer. Expert Rev Anticancer Ther. 2016;16(6):643–652.
   PubMed Web of Science ®Google Scholar
• Liu R, Wei H, Gao P, et al. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 2017;8(24):39021–39032.
   PubMedGoogle Scholar
• Cho U, Kim B, Kim S, et al. Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF-kappaB activation. Mol Carcinog. 2018;57(2):235–242.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang L, Yan G, et al. Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: a Meta-Analysis. Biomed Res Int. 2017;2017:7943467.
   PubMed Web of Science ®Google Scholar